PRINCETON, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Company (NASDAQ: IART), a leading global medical technology company, today issued its latest Environmental, Social and Governance (ESG) report. The report highlights the company’s 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago.
“Innovating treatment pathways to advance patient outcomes and set new standards of care is work that matters to our Integra colleagues around the world and is what drives us each and every day,” said Jan De Witte, president and chief executive officer, Integra LifeSciences. “We are pleased with the advances we have made to meet our ESG commitments and ambitions as we play our part to create healthier people, a healthier workplace and a healthier world.”
Integra’s ESG report includes the past year’s highlights in key areas:
Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index.
Read the full report here.
About Integra
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit investor.integralife.com.
Contacts:
Investors:
Chris Ward
(609) 936-2322
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$21.80 |
Daily Change: | 0.09 0.41 |
Daily Volume: | 1,114,613 |
Market Cap: | US$1.680B |
November 13, 2024 November 04, 2024 November 04, 2024 September 04, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB